INVIVYD, INC. Investing Cash Flow
INVIVYD, INC. (IVVD) reported Investing Cash Flow of -$1.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-13
- INVIVYD, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$510.00K.
- INVIVYD, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$726.00K.
- INVIVYD, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- INVIVYD, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $0.00.
- INVIVYD, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$155.00K.
- INVIVYD, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$140.00K, a 100.05% decline from fiscal 2023.
- INVIVYD, INC. net cash provided by (used in) investing activities for fiscal 2023 was $280.68M.
- INVIVYD, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$230.67M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 4 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 7 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$510.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.24M 10-Q · filed 2026-08-13 | -$1.24M derived: sum of 3 quarters · filed 2026-08-13 | -$1.24M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | -$726.00K 10-Q · filed 2026-05-14 | -$726.00K derived: sum of 2 quarters · filed 2026-05-14 | -$726.00K derived: sum of 3 quarters · filed 2026-05-14 | -$737.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | -$11.00K derived: sum of 3 quarters · filed 2026-08-13 | -$155.00K 10-K · filed 2026-03-05 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$11.00K derived: sum of 2 quarters · filed 2026-08-13 | -$155.00K 10-Q · filed 2025-11-06 | -$150.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$155.00K 10-Q · filed 2026-08-13 | -$150.00K derived: sum of 3 quarters · filed 2026-08-13 | -$155.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$144.00K 10-Q · filed 2026-05-14 | -$139.00K derived: sum of 2 quarters · filed 2026-05-14 | -$144.00K derived: sum of 3 quarters · filed 2026-05-14 | -$144.00K derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | -$140.00K 10-K · filed 2026-03-05 | ||
| 2024-09-30 | -$5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$5.00K derived: sum of 2 quarters · filed 2025-11-06 | -$145.00K 10-Q · filed 2025-11-06 | $77.77M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$140.00K 10-Q · filed 2025-08-14 | $77.78M derived: sum of 3 quarters · filed 2025-08-14 | $172.91M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | -$140.00K 10-Q · filed 2025-05-15 | $77.78M derived: sum of 2 quarters · filed 2025-05-15 | $172.91M derived: sum of 3 quarters · filed 2025-05-15 | $205.51M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $77.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $173.05M derived: sum of 2 quarters · filed 2025-03-20 | $205.65M derived: sum of 3 quarters · filed 2025-03-20 | $280.68M 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $95.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $127.73M derived: sum of 2 quarters · filed 2024-11-14 | $202.77M 10-Q · filed 2024-11-14 | $63.95M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $32.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $107.63M 10-Q · filed 2024-08-14 | -$31.18M derived: sum of 3 quarters · filed 2024-08-14 | -$172.02M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $75.04M 10-Q · filed 2024-05-09 | -$63.78M derived: sum of 2 quarters · filed 2024-05-09 | -$204.61M derived: sum of 3 quarters · filed 2024-05-09 | -$204.63M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$138.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$279.65M derived: sum of 2 quarters · filed 2024-03-28 | -$279.67M derived: sum of 3 quarters · filed 2024-03-28 | -$230.67M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | -$140.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$140.85M derived: sum of 2 quarters · filed 2023-11-09 | -$91.85M 10-Q · filed 2023-11-09 | $46.06M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-06-30 | -$17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $48.98M 10-Q · filed 2023-08-10 | $186.90M derived: sum of 3 quarters · filed 2024-02-09 | -$1.73M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-03-31 | $49.00M 10-Q · filed 2023-05-11 | $186.92M derived: sum of 2 quarters · filed 2024-02-09 | -$1.71M derived: sum of 3 quarters · filed 2024-02-09 | -$1.71M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2021-12-31 | $137.92M derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09 | -$50.71M derived: sum of 2 quarters · filed 2024-02-09 | -$50.71M derived: sum of 3 quarters · filed 2024-02-09 | -$50.71M 8-K · filed 2024-02-09 | ||
| 2021-09-30 | -$188.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$188.63M derived: sum of 2 quarters · filed 2022-11-10 | -$188.63M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-13 | |||||
| 2020-12-31 | $0.00 10-K · filed 2022-03-31 | |||||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |